| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$1,329,156 ) |
| | 2025 | 2023 | VXBIOSCIENCES, INC | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R42AI174554 | Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients | 000 | 1 | NIH | 5/1/2025 | $0 |
| | 2025 | 2023 | VXBIOSCIENCES, INC | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R01AI169443 | Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | 000 | 1 | NIH | 2/10/2025 | -$1,329,156 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | VXBIOSCIENCES, INC. | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R01AI169443 | Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | 001 | 1 | NIH | 1/22/2024 | $0 |
| | 2024 | 2021 | VXBIOSCIENCES, INC. | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R01AI169443 | Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | 000 | 1 | NIH | 1/22/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,297,089 ) |
| | 2023 | 2023 | VXBIOSCIENCES, INC. | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R42AI174554 | Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients | 000 | 1 | NIH | 9/12/2023 | $300,000 |
| | 2023 | 2023 | VXBIOSCIENCES, INC. | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R01AI169443 | Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | 001 | 1 | NIH | 7/12/2023 | $1,997,089 |
| | 2023 | 2021 | VXBIOSCIENCES, INC. | 1431 CENTER ST APT 201 | OAKLAND | CA | 94607-2065 | ALAMEDA | USA | R01AI169443 | Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | 000 | 1 | NIH | 7/11/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,820,494 ) |
| | 2021 | 2021 | VXBIOSCIENCES, INC. | 945 SUNNYHILLS RD | OAKLAND | CA | 94610-2414 | ALAMEDA | USA | R01AI169443 | Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | 000 | 1 | NIH | 9/24/2021 | $2,820,494 |
|
|
